Regan Group Reaches 22.1% of CDT Equity as $195K Fee and $65K Severance Convert to Stock
CDT is trading near its 52-week low of $0.076 (7.8% above the low) on elevated volume (4.0× avg).
Summary
CDT Equity issued 1,347,616 shares to Andrew Regan's Manoira at $0.1447 to settle a $195,000 evaluation fee, and 499,616 shares to Regan at $0.1301 for $65,000 of severance. The Regan group now holds 22.1% of the company.
Key Events · Ownership and Investor Activity · CDT
-
Related-Party Fee Paid in Stock
Manoira, 87% owned by Regan's Corvus, received 1,347,616 shares at $0.1447 per share to satisfy a $195,000 Evaluation Agreement fee dated October 22, 2026.
-
Severance Converted to Equity
Regan converted $65,000 of remaining severance into 499,616 shares at $0.1301 per share on October 23, 2026, leaving $235,000 of the original $300,000 unpaid.
-
Regan Group at 22.1%
Regan beneficially owns 2,064,698 shares (22.1%) of the 9,322,805 shares outstanding as of October 23, 2026; Corvus reports 16.8% and Manoira 14.5%.
-
Conversion Prices Above Market
Both conversions were struck at $0.1447 and $0.1301 versus today's $0.0819 quote—cash saved, but shares issued at roughly 1.6-1.8x the current price.
Analysis · CDT · Life Sciences
CDT Equity settled a $195,000 evaluation fee to Manoira—87% owned by Andrew Regan's Corvus Capital—entirely in stock, and separately converted $65,000 of Regan's remaining severance into shares. Both conversions were priced well above today's $0.0819 quote ($0.1447 and $0.1301), so the company preserved cash but issued paper at roughly 1.6-1.8x the current market price. The Regan group now controls 22.1% of the 9,322,805 shares outstanding, up from prior levels, concentrating voting power in the hands of the former CEO and his vehicles while the company asks shareholders on November 12 to approve yet more shares for the J.J. Astor convertible note. Related-party terms and the rising insider stake are the two things that matter here.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 31% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDT was trading at $0.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $90K. The 52-week trading range was $0.08 to $20,123.75. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.